We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The competitive acquisition program (CAP) for Medicare Part B drugs will include 181 products when it is implemented Jan. 1, 2006, according to a Centers for Medicare & Medicaid Services’ (CMS) interim final rule on the program.
The HHS Inspector General (IG) has cleared acting FDA Commissioner Lester Crawford of anonymous allegations of impropriety, clearing the way for the Senate to proceed with a confirmation vote on Crawford’s nomination to become commissioner of the agency.
A panel of independent health experts has recommended against the routine use of estrogen to prevent chronic diseases in postmenopausal women who have undergone a hysterectomy.
Potential drug plan sponsors of the Medicare prescription drug benefit submitted more than 300 formulary applications to the Centers for Medicare & Medicaid Services (CMS) by the April 22 deadline.
A large percentage of investigators conducting medical research have not had proper training and are rarely credentialed by an accreditation organization, according to clinical trials experts, many of whom are concerned about the quality of future clinical studies and the integrity of those who will oversee them.
The federal government and the clinical trials industry are discussing the possibility of drafting guidelines, or even formal regulations, to ensure universities and clinical research institutions are not engaging in detrimental activities that create conflicts of interest.
The Centers for Medicare & Medicaid Services (CMS) has not yet started reviewing the more than 300 formulary applications submitted by potential drug plan sponsors of the Medicare prescription drug benefit.
The NIH has launched a new initiative that it hopes will lead to better coordination of federal policies governing research activities, according to a top agency official.
The Centers for Medicare & Medicaid Services (CMS) has placed its top medical officer on administrative leave for allegedly falsifying documents and refusing to comply with a state medical board’s investigation into the matter.
The Centers for Medicare & Medicaid Services (CMS) has expanded its coverage of Medicare Part B drugs to include Merck’s oral, anti-nausea treatment Emend.